Tag: bi-specific MAbs market outlook

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Bi-Specific MAbS Industry By The Forecast Year 2029?

The bi-specific MAbS market has seen a rapid expansion in its size over recent years. It is anticipated to expand from $7.83 billion in 2024 to $9.05 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.5%. Historically, this market’s growth can be attributed to factors such as elevated healthcare expenditure, increased funding, and various government initiatives.

The bi-specific MAbS market is anticipated to experience substantial growth over the next few years, with projections indicating it will expand to $14.89 billion by 2029, achieving a compound annual growth rate (CAGR) of 13.3%. This expansion during the forecast period is primarily driven by the increasing incidence of cancer, a growing aging population, and a rise in the prevalence of chronic diseases. Prominent trends for this period include a dedicated focus on technological advancements, continuous product innovation, the integration of artificial intelligence, increased investment in targeted and combination therapies, and the establishment of strategic partnerships.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Are The Top Growth Drivers Impacting The Bi-Specific MAbS Market Outlook?

The rising prevalence of cancer and other chronic diseases is expected to fuel the growth of the bispecific monoclonal antibodies market throughout the forecast period. Bispecific monoclonal antibodies are created for the treatment of diverse cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. These antibodies are regarded as more effective than traditional monoclonal antibodies (moAbs) since they target two or more tumor antigens on cells to impede cancer progression. For instance, in 2023, the Cancer Facts & Figures 2023 report, published by the American Cancer Society (ACS), a US-based voluntary health organization, estimated 609,820 cancer-related fatalities in the USA. Consequently, an increasing number of chronic diseases, including cancer, is anticipated to boost the demand for bi-specific MAbs to effectively treat these conditions.

Which Key Segments Fueling The Bi-Specific MAbS Market?

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

What Trends Are Expected To Drive The Bi-Specific MAbS Market?

Firms within the bi-specific MAbs market are progressively channeling resources into diverse strategic endeavors, including cooperative agreements and alliances, aimed at broadening their product range and global footprint. Such a collaboration involves a cooperative venture among multiple organizations designed to achieve shared objectives. As an illustration, during October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical firms, initiated an exclusive partnership. This collaboration focuses on the development of MGD024, a bispecific antibody that targets CD123 and CD3 utilizing MacroGenics’ DART platform, alongside two additional bispecific research initiatives. This alliance provides Gilead with an exclusive licensing option for MGD024, a compound with the potential to address various hematologic cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to reduce cytokine-release syndrome (CRS) and permit intermittent administration, which could result in a more tolerable treatment experience and enhanced clinical results for patients suffering from AML and MDS.

Which Major Industry Participants Are Leading The Bi-Specific MAbS Market Growth?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Bi-Specific MAbS Market Report:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Browse Through More Reports Similar to the Global Bi-Specific MAbS Market 2025, By The Business Research Company

Anti Hypertensive Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Pharmaceutical Api Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Microbiome Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Bi-Specific MAbS Market?

The size of the bi-specific MAbS market has seen a rapid expansion in the past few years. An increase from $7.83 billion in 2024 to $9.05 billion in 2025, with a compound annual growth rate (CAGR) of 15.5% is projected. The amplified spending on healthcare, heightened funding and initiatives by the government are identified as key factors that contributed to this growth in the previous years.

Expectations are high for the bi-specific MAbS market to experience rapid expansion in the coming years. The market is projected to surge to “$14.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.3%. This significant growth during the forecast period can be attributed to the rising incidence of cancer, an ageing population, and escalating prevalence of chronic illnesses. Key trends anticipated throughout the forecast period include technological advancement, product innovation, increased reliance on artificial intelligence, investments in targeted and combined therapy, and the formation of strategic partnerships.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Which Factor Is Shaping The Future Of The Bi-Specific MAbS Market?

The escalating incidence of cancer and other chronic illnesses is expected to fuel the expansion of the bispecific monoclonal antibodies market in the forecasted timeline. Bispecific monoclonal antibodies, designed to combat various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders, are seen as more potent than monoclonal antibodies (moAbs) since they target multiple tumor antigens on the cells to halt cancer progression. For instance, the American Cancer Society (ACS), a volunteer health organization based in the US, predicts 609,820 cancer-related fatalities in the US in 2023, as stated in their 2023 Cancer Facts & Figures report. Consequently, an increasing prevalence of chronic illnesses, including cancer, is likely to drive demand for bi-specific MAbs as an effective treatment option.

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

What Upcoming Trends Are Expected To Impact The Bi-Specific MAbS Market Globally?

Bi-specific MAbs market players are ramping up investments in key strategic endeavours such as partnerships and collaborations, with an aim to widen their product range and enhance their global reach. Strategic collaboration typically involves two or more organizations working together to realise shared objectives or aims. An illustration of this was in October 2022 when Gilead Sciences and MacroGenics, both American biopharmaceutical companies, formed an exclusive partnership to develop MGD024, a bispecific antibody targeting CD123 and CD3, using MacroGenics’ DART platform, in addition to two other bispecific research programs. As part of this collaboration, Gilead has the sole option to license MGD024, which has the capability to treat an array of hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to curb cytokine-release syndrome (CRS) and to facilitate intermittent dosing, which could lead to more patient-friendly treatments and better clinical results for AML and MDS patients.

Which Companies Hold The Largest Market Share In The Bi-Specific MAbS Sector?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

How Does Regional Performance Compare Across The Bi-Specific MAbS Industry?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Bi-Specific MAbS Market, and What Factors Will Drive It?

The market size of bi-specific MAbS has seen an accelerated increase in recent times. It is projected to escalate from $7.83 billion in 2024, reaching $9.05 billion in 2025, with a compound annual growth rate (CAGR) of 15.5%. Factors such as higher healthcare spending, boosted funds, and official government actions account for the historic period’s growth.

The market of bi-specific MAbS is projected to experience swift expansion in the forthcoming years, with an estimated valuation of $14.89 billion by 2029; this represents a compound annual growth rate (CAGR) of 13.3%. The expected growth over the forecast period is primarily due to the rising prevalence of cancer, growth in the elderly population, and increase in chronic diseases incidence. Key trends identified for the forecast period include technological advancements, product innovation, artificial intelligence emphasis, investment in targeted and combination therapy, as well as strategic collaborative efforts.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What External and Internal Drivers Are Contributing to the Growth of theBi-Specific MAbS Market?

The growth of the bispecific monoclonal antibodies market is anticipated to be driven by the increasing incidence of cancer and other chronic diseases during the forecast period. Developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders, bispecific monoclonal antibodies are believed to be more potent than monoclonal antibodies (moAbs). This is because they target two or more antigens on tumor cells to hinder the advancement of cancer. According to the American Cancer Society’s (ACS) Cancer Facts & Figures 2023 report, in 2023, there are predicted to be around 609,820 cancer-related fatalities in the USA. Consequently, the rising prevalence of cancer and other chronic diseases is projected to fuel demand for bi-specific MAbs as a highly efficient treatment option.

What Segment Types Define the Bi-Specific MAbS Market Structure?

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Bi-Specific MAbS Market?

Businesses in the bi-specific MAbs market are progressively investing in strategic measures such as alliances and partnerships to enhance their product range and broaden their geographic footprint. A strategic partnership is a synergy between two or more companies aimed at achieving mutual objectives or goals. For example, in October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical firms, formed an exclusive partnership to develop MGD024, a bispecific antibody targeting CD123 and CD3 developed using MacroGenics’ DART platform, along with two other bispecific research initiatives. Gilead has been granted exclusive licensing options for MGD024 as part of this collaboration, which is believed to hold promise for the treatment of multiple blood-related cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to alleviate cytokine-release syndrome (CRS) symptoms and facilitate periodic dosing, potentially resulting in more patient-centric care and superior clinical outcomes for AML and MDS patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

What Is the Definition of the Bi-Specific MAbS Market?

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What is the Anticipated CAGR of the Bi-Specific MAbS Market, and What Factors Will Drive It?#_x000D_

The market size of bi-specific MAbS has seen an accelerated increase in recent times. It is projected to escalate from $7.83 billion in 2024, reaching $9.05 billion in 2025, with a compound annual growth rate (CAGR) of 15.5%. Factors such as higher healthcare spending, boosted funds, and official government actions account for the historic period’s growth._x000D_

_x000D_

The market of bi-specific MAbS is projected to experience swift expansion in the forthcoming years, with an estimated valuation of $14.89 billion by 2029; this represents a compound annual growth rate (CAGR) of 13.3%. The expected growth over the forecast period is primarily due to the rising prevalence of cancer, growth in the elderly population, and increase in chronic diseases incidence. Key trends identified for the forecast period include technological advancements, product innovation, artificial intelligence emphasis, investment in targeted and combination therapy, as well as strategic collaborative efforts._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp_x000D_

_x000D_

#What External and Internal Drivers Are Contributing to the Growth of theBi-Specific MAbS Market?#_x000D_

The growth of the bispecific monoclonal antibodies market is anticipated to be driven by the increasing incidence of cancer and other chronic diseases during the forecast period. Developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders, bispecific monoclonal antibodies are believed to be more potent than monoclonal antibodies (moAbs). This is because they target two or more antigens on tumor cells to hinder the advancement of cancer. According to the American Cancer Society’s (ACS) Cancer Facts & Figures 2023 report, in 2023, there are predicted to be around 609,820 cancer-related fatalities in the USA. Consequently, the rising prevalence of cancer and other chronic diseases is projected to fuel demand for bi-specific MAbs as a highly efficient treatment option._x000D_

_x000D_

#What Segment Types Define the Bi-Specific MAbS Market Structure?#_x000D_

The bi-specific mabs market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab_x000D_

2) By Product Type: In Vivo, In Vitro_x000D_

3) By Indication: Cancer, Haemophilia A, Ophthalmic_x000D_

4) By End Use: Hospitals, Research Institutes, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3 _x000D_

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3 _x000D_

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR) _x000D_

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X _x000D_

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET _x000D_

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A _x000D_

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3 _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Bi-Specific MAbS Market?#_x000D_

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#What Long-Term Trends Are Transforming the Competitive Landscape of the Bi-Specific MAbS Market?#_x000D_

Businesses in the bi-specific MAbs market are progressively investing in strategic measures such as alliances and partnerships to enhance their product range and broaden their geographic footprint. A strategic partnership is a synergy between two or more companies aimed at achieving mutual objectives or goals. For example, in October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical firms, formed an exclusive partnership to develop MGD024, a bispecific antibody targeting CD123 and CD3 developed using MacroGenics’ DART platform, along with two other bispecific research initiatives. Gilead has been granted exclusive licensing options for MGD024 as part of this collaboration, which is believed to hold promise for the treatment of multiple blood-related cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to alleviate cytokine-release syndrome (CRS) symptoms and facilitate periodic dosing, potentially resulting in more patient-centric care and superior clinical outcomes for AML and MDS patients._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report_x000D_

_x000D_

#What Is the Definition of the Bi-Specific MAbS Market?#_x000D_

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Forecast for the Bi-Specific MAbS Market Growth in 2025?#_x000D_

The market size for bi-specific MAbS has experienced fast-paced growth in recent years. Predictions indicate it will escalate from $7.83 billion in 2024 to $9.1 billion in 2025, presenting a compound annual growth rate (CAGR) of 16.2%. The notable escalation in the past was a result of increased healthcare spending, augmented funding, and initiatives taken by the government._x000D_

_x000D_

#What Is the Forecast for the Bi-Specific MAbS Market Size Through 2029?#_x000D_

In the coming years, the bi-specific MAbS market is projected to experience a swift expansion. By 2029, it’s anticipated to reach a value of $15.19 billion, with a compound annual growth rate (CAGR) of 13.7%. This growth in the forecast period can be attributed to factors such as a rising prevalence of cancer, an aging population, and an increase in chronic disease incidence. Key trends during this period include an emphasis on technological advancements, innovation in products, the integration of artificial intelligence, investment in targeted and combination therapies, and the cultivation of strategic partnerships._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp_x000D_

_x000D_

#What are the Key Market Players in Bi-Specific MAbS Market and How They’re Evolving?#_x000D_

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa_x000D_

_x000D_

#What Are the Primary Growth Drivers in the Bi-Specific MAbS Market?#_x000D_

The surging occurrence of cancer and other long-lasting diseases is expected to fuel the expansion of the bispecific monoclonal antibodies market in the coming years. These antibodies are formulated for therapy options in multiple conditions like cancers, infectious diseases, disorders affecting the central nervous system, and autoimmune disorders. Bispecific monoclonal antibodies are deemed more potent than their monoclonal counterparts as they target more than one tumor antigen on the cells, thereby hindering the progression of cancer. For instance, the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a voluntary health organization in the US, predicts that there will be roughly 609,820 deaths related to cancer in the USA by 2023. As such, the escalating incidence of chronic diseases, cancer included, is predicted to boost the demand for bi-specific monoclonal antibodies for effective treatment._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp_x000D_

_x000D_

#What Are the Leading Segments in the Global Bi-Specific MAbS Industry?#_x000D_

The bi-specific MAbS market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab_x000D_

2) By Product Type: In Vivo, In Vitro_x000D_

3) By Indication: Cancer, Haemophilia A, Ophthalmic_x000D_

4) By End Use: Hospitals, Research Institutes, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3_x000D_

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3_x000D_

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)_x000D_

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X_x000D_

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET_x000D_

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A_x000D_

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3_x000D_

_x000D_

#What Are the Key Market Trends in the Bi-Specific MAbS Industry?#_x000D_

Businesses in the bi-specific MAbs sector are demonstrating a growing trend of investing in strategic initiatives such as collaborations and partnerships to broaden their product offerings and increase their global reach. A strategic collaboration is essentially a cooperative alliance between multiple organizations intending to accomplish shared objectives or goals. An example of this occurred in October 2022, when Gilead Sciences, a US-based biopharmaceutical firm, and MacroGenics, another US-based biopharmaceutical company, formed an exclusive partnership to progress the development of MGD024, a bispecific antibody aimed at CD123 and CD3, leveraged by MacroGenics’ DART platform, in addition to two other bispecific research programs. This partnership provides Gilead an exclusive option to license MGD024, which could potentially serve as a treatment for several hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 has been created to reduce cytokine-release syndrome (CRS) and moderate the dosing regimen, which could potentially lead to improved treatment experiences for patients and better clinical outcomes for individuals diagnosed with AML and MDS._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report_x000D_

_x000D_

#What Is the Regional Outlook for the Bi-Specific MAbS Market?#_x000D_

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the bi-specific mabs market, and how is it changing globally?_x000D_

2. Who are the major companies in the bi-specific mabs market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the bi-specific mabs market right now?_x000D_

4. Which products or customer segments are growing the most in the bi-specific mabs market?_x000D_

5. What factors are helping or slowing down the growth of the bi-specific mabs market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the bi-specific mabs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has The Bi-Specific MAbS Market Size Shifted, And What Is the Outlook Through 2034?

The market size of bi-specific MAbS has witnessed a swift expansion in the past few years. The market which is projected to climb from $7.83 billion in 2024 to $9.1 billion in 2025, echoes a compound annual growth rate (CAGR) of 16.2%. Factors such as elevated healthcare expenditure, augmented funding and various government schemes have contributed to the growth observed in the historical phase.

The market size of bi-specific MAbS is anticipated to witness a swift expansion in the coming years. The market is projected to reach $15.19 billion in 2029, with a compound annual growth rate (CAGR) of 13.7%. This growth during the forecasted period can be credited to the rising incidence of cancer, heightened aging populace, and a surge in chronic disease prevalence. The key trends predicted for this period involve an emphasis on technological progress, product novelty, the use of artificial intelligence, investment in specialized and combination therapy, as well as tactical collaborations.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Bi-Specific MAbS Market?

The escalating incidence of cancer and other chronic diseases is expected to fuel the expansion of the bispecific monoclonal antibodies market in the predicted timeline. Bispecific monoclonal antibodies, designed for treating various cancers, infectious diseases, disorders of the central nervous system, and autoimmune disorders, are deemed more potent than monoclonal antibodies (moAbs) as they target multiple tumor antigens on cells to hinder the progression of cancer. As an example, the Cancer Facts & Figures 2023 report by the American Cancer Society (ACS), a voluntary health institution based in the US, predicts about 609,820 cancer-related deaths in the US in 2023. Thus, an escalating count of chronic diseases, including cancer, is expected to drive the demand for bi-specific MAbs as an effective treatment for these diseases.

Which Key Market Segments Comprise the Bi-Specific MAbS Market and Drive Its Revenue Growth?

The bi-specific MAbS market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Which Areas Are Leading Regions in the Bi-Specific MAbS Market Expansion Across the Globe?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Key Market Trends in theBi-Specific MAbS Market Over the Coming Years?

Firms operating in the bi-specific MAbs market are progressively investing in strategic initiatives like partnerships and collaborations to broaden their product range and enhance their global footprint. A strategic alliance is a cooperative arrangement between two or more entities aimed at achieving shared objectives. For instance, in October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical corporations, announced an exclusive collaboration to work on MGD024, a bispecific antibody aimed at CD123 and CD3, using MacroGenics’ DART platform, as well as two other bispecific research programs. The partnership gives Gilead the exclusive option to license MGD024, with potential applications in treating a variety of hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Moreover, MGD024 is engineered to reduce cytokine-release syndrome (CRS) and enable intermittent dosing, which could lead to more patient-friendly treatment protocols and enhanced clinical outcomes for AML and MDS patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

How Is the Bi-Specific MAbS Market Conceptually Defined?

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Bi-Specific MAbS Market?

The expected growth in the bispecific monoclonal antibodies market is predicted to be driven by the rising incidence of cancer and various other chronic illnesses. These particular antibodies are used in the treatment of several conditions like cancer, infectious diseases, disorders related to the central nervous system, and autoimmune diseases. Compared to monoclonal antibodies (moAbs), bispecific monoclonal antibodies are believed to be more effective, as they target multiple tumor antigens on cells to inhibit cancer progression. To illustrate, the Cancer Facts & Figures 2023 report from the American Cancer Society (ACS), a voluntary health organization in the US, predicts about 609,820 cancer-related fatalities in the USA by 2023. Consequently, the increased prevalence of chronic conditions, including cancer, is likely to boost the demand for bispecific monoclonal antibodies for a more effective treatment.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

#What Long-Term Growth Rate is Expected for theBi-Specific MAbS Market Between 2025 and 2034?

The market size for bi-specific MAbS has seen substantial growth recently and is predicted to expand from $7.83 billion in 2024 to $9.1 billion in 2025 with a compound annual growth rate (CAGR) of 16.2%. This progress during the historic period is largely due to the rise in healthcare spending, amplified funding, and initiatives from the government.

The market for bi-specific MAbS is anticipated to experience a fast-paced expansion over the coming years. The market size is projected to reach $15.19 billion by 2029, with a compound annual growth rate (CAGR) of 13.7%. This growth during the forecasted period can be linked to the rising incidence of cancer, an aging population, and a growth in chronic disease cases. In the prediction period, prevalent trends involve emphasis on technological progress, product innovation, the application of artificial intelligence, investments in targeted and combination treatments, as well as strategic collaborations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

What Are the Key Market Innovations in theBi-Specific MAbS Market Over the Coming Years?

In an attempt to widen their product offering and extend their geographic reach, businesses in the bi-specific MAbs industry are progressively putting their resources into strategic endeavors, such as alliances and partnerships. A strategic partnership occurs when two or more firms work cooperatively to achieve shared aims or goals. To illustrate, Gilead Sciences and MacroGenics, both biopharmaceutical firms based in the US, forged an exclusive alliance in October 2022. The partnership aims to develop MGD024, a bispecific antibody targeting CD123 and CD3, using MacroGenics’ DART platform, in conjunction with two other bispecific research initiatives. This partnership gives Gilead the exclusive right to license MGD024, which shows promise in treating a variety of hematologic cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 has been engineered to reduce cytokine-release syndrome (CRS), allowing for intermittent dosing, which could potentially result in a more patient-oriented approach to treatment and better clinical results for those suffering from AML and MDS.

Who Are the Top Companies Driving Innovation and Growth in theBi-Specific MAbS Market?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Key Market Segments Comprise the Bi-Specific MAbS Market and Drive Its Revenue Growth?

The bi-specific MAbS market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Which Regions Are Emerging as Leaders in the Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Bi-Specific MAbS Market 2025, By The Business Research Company:

Microbiome Therapeutics Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Future CAGR is Anticipated for the Bi-Specific MAbS Market Over the 2025–2034 Period?

The bi-specific MAbs market has experienced rapid growth in recent years. It is projected to rise from $7.83 billion in 2024 to $9.1 billion in 2025 at a CAGR of 16.2%. The past growth can be attributed to increased healthcare spending, greater funding, and government initiatives.

The bi-specific monoclonal antibodies market is projected to experience significant growth in the coming years. It is anticipated to reach $15.19 billion by 2029, with a compound annual growth rate (CAGR) of 13.7%. This growth during the forecast period is linked to a rising incidence of cancer, an aging population, and an increase in chronic diseases. Key trends include a focus on technological advancements, product innovation, artificial intelligence, investments in targeted and combination therapies, and strategic partnerships.

What Factors Are Propelling the Growth of the bi-specific mabs Market from 2025 to 2034?

The rising prevalence of chronic diseases like cancer is expected to drive the demand for bispecific monoclonal antibodies (bi-specific MAbs). These antibodies target multiple tumor antigens, making them more effective at treating cancers and other chronic diseases. As the number of cancer diagnoses continues to grow, the market for bispecific monoclonal antibodies will likely expand to meet the demand for more targeted and effective treatments.

Explore Comprehensive Insights Into The Global Bi-Specific MAbS Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Who Are the Influential Players Fueling Innovation and Growth in the Bi-Specific MAbS Market?

Major companies operating in the bi-specific MAbS market include:

• F. Hoffmann-La Roche AG_x000D_

• Amgen Inc_x000D_

• Johnson & Johnson_x000D_

• Sino Biological Inc_x000D_

• Kyowa Kirin_x000D_

What Impact Are Industry Trends Having on the Bi-Specific MAbS Market’s Future Prospects?

Companies in the bi-specific monoclonal antibodies (MAbs) market are increasingly investing in strategic initiatives such as collaborations and partnerships to expand their product portfolios and global presence. A strategic partnership refers to a cooperative agreement between organizations to achieve shared goals. For example, in October 2022, Gilead Sciences, a US-based biopharmaceutical company, and MacroGenics, another US-based biopharmaceutical firm, entered an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3, using MacroGenics’ DART platform, along with two other bispecific research projects. This partnership grants Gilead an exclusive option to license MGD024, a potential treatment for hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed to minimize cytokine-release syndrome (CRS) while allowing intermittent dosing, making treatment more patient-friendly and improving clinical outcomes for AML and MDS patients.

Secure Your Global Bi-Specific MAbS Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Key Segments Define the Structure of the Bi-Specific MAbS Market and Their Growth Potential?

The bi-specific MAbS market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

What Regions Are Leading the Growth Trajectory of the Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Do Experts Define the Scope of the Bi-Specific MAbS Market?

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy.

Browse Through More Similar Reports By The Business Research Company:

Microbiome Therapeutics Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the bi-specific mabs market right now?

Over the previous years, the market size of bi-specific MAbS has witnessed a swift expansion. The market value is projected to rise from $7.83 billion in 2024 to $9.1 billion in 2025, translating to a compound annual growth rate (CAGR) of 16.2%. Factors contributing to this growth during the historical period include elevated healthcare spending, augmented funding, and government interventions.

How fast Is the bi-specific mabs market expected to grow, and what’s its future value?

In the coming years, the bi-specific MAbS market is forecasted to experience an accelerated pace of expansion. The market is set to reach a whopping $15.19 billion by the year 2029, representing a compound annual growth rate (CAGR) of 13.7%. Factors believed to contribute to this escalated growth within the projected time frame include the rising incidence of cancer, population aging, and an increased prevalence of chronic illnesses. Key trends projected for this period include an emphasis on technological advancements, product innovation, the use of artificial intelligence, investments in targeted and combination therapy, as well as the formation of strategic partnerships.

Get your bi-specific mabs market report here!

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

What are the leading drivers of growth in the bi-specific mabs market?

Forecasted growth in the bispecific monoclonal antibodies market is expected due to the rise in prevalence of cancer and other chronic illnesses. These antibodies are specially engineered for targeting various health conditions including cancers, infectious ailments, disorders of the central nervous system, and autoimmune diseases. The advantage of bispecific monoclonal antibodies over monoclonal antibodies is their ability to target two or more antigens on cells, thus inhibiting the progress of cancer. For example, as per the Cancer Facts & Figures 2023 report by the American Cancer Society, a voluntary health organization based in the US, it is predicted that there will be around 609,820 cancer fatalities in the USA in 2023. Therefore, owing to the expected rise in chronic illnesses, most notably cancer, the requirement for bi-specific MAbs, which are highly effective in treating these conditions, is projected to surge.

What are the key segments defining the bi-specific mabs market?

The bi-specific MAbS market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Who are the key players steering the development of the bi-specific mabs market?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

What emerging trends are influencing the growth of the bi-specific mabs market?

In an effort to broaden their product range and global reach, companies in the bi-specific MAbs market are increasingly pursuing strategic avenues such as collaborations and partnerships. A strategic collaboration comprises a mutual partnership between two or more organizations with the objective of fulfilling shared aims or goals. One such example is the exclusive partnership in October 2022 between Gilead Sciences and MacroGenics, both US-based biopharmaceutical companies. This collaboration involved the development of MGD024, a bispecific antibody targeting CD123 and CD3. The partnership also included two other bispecific research programs. This development bestowed exclusive rights to Gilead to license MGD024, which holds promise as a treatment for various hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to reduce cytokine-release syndrome (CRS) and allows for intermittent dosage, potentially making treatment more comfortable for patients and improving clinical outcomes for individuals suffering from AML and MDS.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

Which regions are most influential in expanding the bi-specific mabs market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Microbiome Therapeutics Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: